Why Immuron Is Rising In Pre-market?
(RTTNews) - Immuron (IMRN) has submitted an Investigational New Drug application to the FDA for clinical development of IMM-529. The company is proposing the development of IMM-529 for treatment of Clostridioides difficile infection and prevention of recurrent CDI.
The company plans to initiate a Phase 2 trial for IMM-529 in individuals with Clostridioides difficile infection during the first half of 2026. IMM-529 specifically targets Toxin B, the spores, and the surface layer proteins of the vegetative cells.
Shares of Immuron are up 8% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.